Equity · Healthcare
TARS
NASDAQTarsus Pharmaceuticals (TARS)
The line runs 72.82 USD on 24 August through 67.55 USD on 5 November, on a scale from 60 to 100. Days the market did not trade hold the previous close, flat.
- Market cap
- 3.3B USD
- Revenue, year to Dec 2025
- 451.4M USD
- EPS, diluted, year to Dec 2025
- −1.59 USD
- 52-week range
- 56 USD – 90.81 USD
- Avg volume
- 49.5K
as of Nov 5, 2026
Have Tarsus Pharmaceuticals (TARS) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Tarsus Pharmaceuticals insiders reported 8 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 4 Dec 2025, show no open-market purchase.
Form 4, 90 days to 22 Nov 2026, newest reported trade 13 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 13 Nov 2026 | Azamian Bobak R.President/CEO and Board Chair | Sell | 10,000 | 803K USD |
| 15 Sep 2026 | LINK WILLIAM J PHDDirector | Sell | 12,500 | 980K USD |
| 04 Sep 2026 | Azamian Bobak R.President/CEO and Board Chair | Sell | 10,000 | 906K USD |
| 04 Sep 2026 | Lin Elizabeth YeuChief Medical Officer | Sell | 13,953 | 1.2M USD |
| 04 Sep 2026 | Neervannan SeshadriChief Operating Officer | Sell | 4,564 | 388K USD |
| 02 Sep 2026 | Azamian Bobak R.President/CEO and Board Chair | Sell | 10,000 | 801K USD |
| 02 Sep 2026 | Lin Elizabeth YeuChief Medical Officer | Sell | 6,977 | 558K USD |
| 01 Sep 2026 | Lin Elizabeth YeuChief Medical Officer | Sell | 4,601 | 340K USD |
| Sold | 8 open-market sales | 72,595 | $6.00M |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Sep 2026 | LINK WILLIAM J PHDDirector | Option exercise | 201 | |
| 15 Sep 2026 | PYOTT DAVID E IDirector | Option exercise | 201 | |
| 15 Sep 2026 | YARNO WENDY LDirector | Option exercise | 302 |
Which funds hold Tarsus Pharmaceuticals (TARS)?
9 of the 45 institutional funds we track reported a Tarsus Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 220.4M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Held (±25%) | 1,093,868 | 85.5M USD | −23.4% |
| Balyasny Asset Management | New position | 616,404 | 48.5M USD | |
| D. E. Shaw & Co. | Trimmed | 465,025 | 36.6M USD | −34.6% |
| Two Sigma Investments | Added | 183,665 | 14.4M USD | +409.6% |
| Marshall Wace | New position | 148,547 | 11.7M USD | |
| Citadel Advisors | Trimmed | 109,170 | 8.2M USD | −54.8% |
| Point72 Asset Management | New position | 85,000 | 6.7M USD | |
| Renaissance Technologies | Added | 72,100 | 5.7M USD | +675.3% |
| AQR Capital Management | Held (±25%) | 39,991 | 3.1M USD | −4.8% |
| Tudor Investment Corp | Exited |
What has been filed or recorded for Tarsus Pharmaceuticals (TARS)?
The filings we hold for Tarsus Pharmaceuticals, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 17,567 shares | 1.3M USD notional · 0.036% of shares out |
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 896 shares | 65K USD notional · 0.002% of shares out |
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 86 shares | 6K USD notional · <0.001% of shares out |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 22,500 shares | 1.6M USD notional · 0.046% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −14.40 USD | Revenue $195M |
| 30 Sep 2026 | Financials | Total assets | 505.5M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 104.0M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.43 USD | Revenue $174M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.16 USD | Revenue $162M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.59 USD | Revenue $451M |
| 31 Dec 2025 | Financials | Revenue | 451.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −66.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.59 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.30 USD | Revenue $119M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.48 USD | Revenue $103M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.64 USD | Revenue $78M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −3.07 USD | Revenue $183M |
What do people ask about Tarsus Pharmaceuticals (TARS)?
What did Tarsus Pharmaceuticals shares close at?67.55
Tarsus Pharmaceuticals closed at 67.55 USD on 5 Nov 2026, down 2.20% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Tarsus Pharmaceuticals’ market cap?3.3B
Tarsus Pharmaceuticals is worth 3.3B USD by market value as of 5 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Tarsus Pharmaceuticals’ revenue?451.4M
Tarsus Pharmaceuticals reported revenue of 451.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Tarsus Pharmaceuticals insiders bought or sold shares recently?8 sales
In the 90 days to 22 Nov 2026, Tarsus Pharmaceuticals insiders reported 8 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 4 Dec 2025, show no open-market purchase. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Tarsus Pharmaceuticals?9 of 45
9 of the 45 funds we track reported a Tarsus Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Balyasny Asset Management and D. E. Shaw & Co. See Funds
When did Tarsus Pharmaceuticals last report earnings?−14.40
Tarsus Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −14.40 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words